Ovarian suppression using a gonadotropin-releasing hormone agonist (GnRHa) with either tamoxifen or with aromatase inhibitors (AIs) is the standard of care in premenopausal women with hormone receptor-positive BC and a high risk of recurrence [5,6]. Here, CYP19A1 is linked to breast cancer.